Search research articles
Contact Us
Filters
Showing results (111-120 of 142) with videos related to
Page
of 15
Sort By:
Bone Marrow Transplantation
|
January 13, 2004
Reduced-intensity conditioning with busulfan and fludarabine with or without antithymocyte globulin in HLA-identical sibling transplantation--a retrospective analysis
J Schetelig, M Bornhäuser, M Kiehl, et al.
Leukemia
|
November 20, 2015
Pretreatment d-2-hydroxyglutarate serum levels negatively impact on outcome in IDH1-mutated acute myeloid leukemia
J Balss, C Thiede, T Bochtler, et al.
Leukemia
|
December 8, 2010
Risk stratification using a new prognostic score for patients with secondary acute myeloid leukemia: results of the prospective AML96 trial
F Stölzel, M Pfirrmann, W E Aulitzky, et al.
Leukemia
|
September 3, 2011
Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial
U Platzbecker, M Wermke, J Radke, et al.
Annals of Hematology
|
May 6, 2004
Imatinib mesylate selectively influences the cellular metabolism of cytarabine in BCR/ABL negative leukemia cell lines and normal CD34+ progenitor cells
M Bornhäuser, T Illmer, P Le Coutre, et al.
Leukemia
|
March 10, 2001
Sequential monitoring of chimerism and detection of minimal residual disease after allogeneic blood stem cell transplantation (BSCT) using multiplex PCR amplification of short tandem repeat-markers
C Thiede, M Bornhäuser, U Oelschlägel, et al.
Blood Cancer Journal
|
July 30, 2016
Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia
S Kayser, A Benner, C Thiede, et al.
Annals of Hematology
|
March 4, 2003
Reduced non-relapse mortality after reduced intensity conditioning in advanced chronic lymphocytic leukemia
J Schetelig, C Thiede, M Bornhäuser, et al.
Leukemia
|
July 11, 2017
Evolution of NPM1-negative therapy-related myelodysplastic syndromes following curative treatment of NPM1-mutant AML
S Herold, K Sockel, C Sayehli, et al.
Leukemia
|
June 8, 2011
Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: a study of the AML-BFM and DCOG study groups
F Damm, F Thol, I Hollink, et al.
Page
of 15
Search research articles
Search
Showing results (111-120 of 142) with videos related to
Sort By:
Page
of 15
Bone Marrow Transplantation
|
January 13, 2004
Reduced-intensity conditioning with busulfan and fludarabine with or without antithymocyte globulin in HLA-identical sibling transplantation--a retrospective analysis
J Schetelig, M Bornhäuser, M Kiehl, et al.
Leukemia
|
November 20, 2015
Pretreatment d-2-hydroxyglutarate serum levels negatively impact on outcome in IDH1-mutated acute myeloid leukemia
J Balss, C Thiede, T Bochtler, et al.
Leukemia
|
December 8, 2010
Risk stratification using a new prognostic score for patients with secondary acute myeloid leukemia: results of the prospective AML96 trial
F Stölzel, M Pfirrmann, W E Aulitzky, et al.
Leukemia
|
September 3, 2011
Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial
U Platzbecker, M Wermke, J Radke, et al.
Annals of Hematology
|
May 6, 2004
Imatinib mesylate selectively influences the cellular metabolism of cytarabine in BCR/ABL negative leukemia cell lines and normal CD34+ progenitor cells
M Bornhäuser, T Illmer, P Le Coutre, et al.
Leukemia
|
March 10, 2001
Sequential monitoring of chimerism and detection of minimal residual disease after allogeneic blood stem cell transplantation (BSCT) using multiplex PCR amplification of short tandem repeat-markers
C Thiede, M Bornhäuser, U Oelschlägel, et al.
Blood Cancer Journal
|
July 30, 2016
Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia
S Kayser, A Benner, C Thiede, et al.
Annals of Hematology
|
March 4, 2003
Reduced non-relapse mortality after reduced intensity conditioning in advanced chronic lymphocytic leukemia
J Schetelig, C Thiede, M Bornhäuser, et al.
Leukemia
|
July 11, 2017
Evolution of NPM1-negative therapy-related myelodysplastic syndromes following curative treatment of NPM1-mutant AML
S Herold, K Sockel, C Sayehli, et al.
Leukemia
|
June 8, 2011
Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: a study of the AML-BFM and DCOG study groups
F Damm, F Thol, I Hollink, et al.
Page
of 15